Background Statins have been associated with later life, long-term care admission in observational studies. However, by preventing vascular events, statins may also prevent or delay admission. We wished to determine statin and long-term care admission associations in a randomised controlled trial context, and describe associations between long-term care admission and other clinical and demographic factors. Methods We used extended follow-up of two randomised trial populations, using national data to assign the long-term care admission outcome, and included individuals screened or recruited to two large randomised trials of pravastatin 40 mg dailythe West of Scotland Coronary Prevention Study (WOSCOPS) and the pravastatin in elderly individuals at risk of vascular disease (PROSPER) study. We described univariable and multivariable analyses of potential predictors of long-term care admission with corresponding survival curves of incident long-term care admission and analyses adjusted for competing risk. Results In total 11,015 (10%) of the trial participants were admitted to long-term care. There was no difference between participants in the statin or placebo arms of either trial in regard to admissions to long-term care. On multivariable analyses, independent associations with incident long-term care admission in the PROSPER trial were age (hazard ratio [HR] 1.06 per year, 95% confidence interval [CI] 1.03-1.09) and male sex (HR 0.72, 95% CI 0.53-0.99). In the WOSCOPS, age (HR 1.12 per year, 95% CI 1.10-1.13) and increasing social deprivation (HR 1.05, 95% CI 1.03-1.08) were associated with incident long-term care admission. Conclusion We did not demonstrate an association between historical statin use and future long-term care admission. The strongest associations with incident long-term care admission were non-modifiable factors of age, sex and socioeconomic deprivation.
Introduction
The benefits of statins (HMG-CoA reductase inhibitors) for reducing cardiovascular events and mortality have been well-described for older adults [1] . Statins have pleiotropic effects, and various non-cardiovascular benefits of statins have been demonstrated [2] . The potential for statins to influence common syndromes of older age, such as functional or cognitive decline, has also been postulated [3] . These statin effects in older age may not necessarily be beneficial and observational data have suggested possible adverse events in relation to physical and cognitive function [4] .
Arguably, the outcomes of greatest relevance to older adults are not mortality or incident vascular events but maintaining functional independence. In other research areas, older adults have expressed that the most desired effect of an intervention is not to prolong life per se but to maintain cognitive and functional ability [5] . The complex construct of independence can be difficult to measure robustly at a population level [6] ; however, admission to institutional long-term care could be viewed as an inversely related measure of independence, where care needs exceed those that can be met in the community. Admission to a care home would be especially relevant to older adults, many of whom have stated that institutionalisation would be a 'fate worse than death' [7] . Admission to long-term care is relatively common, affecting 2-5% of the adult population worldwide [8] , and therefore has potential as a clinical trial outcome of relevance to older adults, physicians and policy makers.
Utilising extended follow-up data from existing statin trial cohorts allows evaluation of the effects of risk modification on later life and allows capture of novel outcomes not collected during the initial study period.
Our aim was to describe associations with long-term care admission using populations from randomised controlled trials (RCTs) of statins. Our primary hypothesis was that statin exposure in mid to older age would be associated with later long-term care admission, while a secondary aim was to assess the feasibility of using admission to long-term care as a trial outcome surrogate for functional decline.
Methods
We conducted extended follow-up of participants and screenees from two large RCTs of the statin pravastatin-the West of Scotland Coronary Prevention Study (WOSCOPS) [8] and the pravastatin in elderly individuals at risk of vascular disease (PROSPER) study [9] .
Trial Data Sources
WOSCOPS was a primary prevention trial conducted in Scotland, UK, between 1989 and 1991, and included male participants aged 45-64 years with raised plasma cholesterol levels [9] . PROSPER was an international trial conducted between 1997 and 1999 for men and women aged 70-82 years who had elevated vascular risk or existing vascular disease [10] . Both studies evaluated the use of pravastatin, at a dose of 40 mg every night, in a randomised, placebo-controlled design. A comprehensive description of baseline characteristics has been previously published [11, 12] . The mean duration of in-trial statin exposure was 4.9 years for WOSCOPS [13] and 3.2 years for PROSPER [10] . Only participants recruited at the Scottish site of PROSPER were included as outcome ascertainment relied on residency in Scotland. All participants and screenees were eligible for inclusion, using baseline data collected at the time of study evaluation and recruitment, and linked to data collected through national health and social care services.
Definition of Covariates
Basic demographic information was available for the entire cohort, including age, sex and socioeconomic status. In addition, some common cardiovascular risk factors were also available. Other clinical and demographic data collected at baseline differed between the studies, therefore the two datasets were not combined. Full details on how the covariates were operationalised are available from the published protocols for the two studies [14, 15] . Socioeconomic status was evaluated using the Carstairs index [14] , an area-based measure of deprivation, based on the postcode of residence. This measure has seven categories, with an increase in category indicative of greater material deprivation [16, 17] . Both sets of trial participants were categorised based on whether they were randomised to the statin arm of the trial in which they participated.
Outcomes
The outcomes of interest were admission to long-term care and death, with long-term care admission defined as being recorded as residing in long-term care at any point during the period 2012-2015. To assign the outcomes, we used a variety of nationally (Scottish) collected data sources [18] . To ensure that the long-term care data were robust, we triangulated three datasets: (1) the Prescribing Information System (which indicates if a drug prescription was issued to a patient registered in a long-term care facility); (2) the Scottish mortality register (which indicates if a patient attending secondary care was discharged to a long-term care facility); and (3) the care-home census (a national annual census of long-term care residents). We described mortality following study completion using National Records of Scotland death registrations data.
Data Linkage
Identifiers for screenees and participants in the clinical trials were securely supplied for linkage with national, centrally held, routine data sources, including names, date of birth, full address and postcode. Each individual was then assigned to a national unique identifier used in Scotland, the Community Health Index (CHI), where available. The CHI is also used within all routine data sources of interest, which allows individual patient-level linkage of datasets.
For our initial study, we were interested in care-home status at specific time points. To this end, given the differences in coverage, it was necessary to harmonise the four possible data sources to analysis. To allow harmonisation across data sources with differing temporal coverage, we focussed on care-home resident status for the period 2012 onwards. Event-based reports (e.g. from Prescribing Information System, Scottish Morbidity/Mortality Records, National Records of Scotland) were not considered if not within the time window of interest.
Following linkage, all identifiable information was removed before the data were made available to the research team through a secured network (safe haven). Data management and analysis was performed at the Robertson Centre for Biostatistics, University of Glasgow.
Statistical Methods
We described univariable-and multivariable-adjusted associations with care-home residents for PROSPER and WOSCOPS separately. For our primary analysis of statin exposure, we ran 'survival' curves using the Kaplan-Meier method, and time-to-event analysis using Cox proportional hazards models, to analyse for association of predictors individually and in multiple regression analyses, censoring on death. Subsequently, competing risk models for residents in a long-term care facility, or death, were created for participants in the two trials.
Approvals
All participants from WOSCOPS and PROSPER consented to the use of their medical records for follow-up. An ethics application was made using the Integrated Research Application System and was approved by the NHS Greater Glasgow and Clyde Health Board, and the Public Benefit and Privacy Panel provided permission to link these data to national health and social care data (eDRIS: 1516-0130). The funding source (Chief Scientist Office, Scotland) played no part in the analyses or interpretation of the data.
Results
A total of 106,242 participants from the original screened population of 117,166 (91%) were indexed and linked to national health and care records. As at March 2015, 56,090 (53%) of participants had died. Between 2012 and 2015, 11,015 (10%) participants were identified, in routine data sources, as having been admitted to long-term care. Overall, 608/6574 (9%) WOSCOPS participants and 482/2033 (24%) participants from PROPSER were admitted to longterm care.
There was no association between in-trial statin exposure and incident long-term care admission. Long-term care residents from the PROSPER study had higher baseline age, were more likely to be female, had higher diastolic blood pressure and higher total cholesterol, were more likely to be smokers, and were more likely to have a history of hypertension, myocardial infarction, peripheral arterial disease and claudication (Table 1) . Long-term care residents from WOSCOPS had higher baseline age, systolic blood pressure, and lower socioeconomic status based on Carstairs category, and were more likely to be current smokers (Table 2) .
On multivariable analyses, independent associations with incident long-term care admission in the PROSPER cohort were age (hazard ratio [HR] 1.06 per year, 95% confidence interval [CI] 1.03-1.09) and a lower risk for those of male sex (HR 0.72, 95% CI 0.53-0.99). In the WOSCOPS cohort, independent associations were age (HR 1.12 per year, 95% CI 1.10-1.13), increasing social deprivation (HR 1.05, 95% CI 1.03-1.08) and smoking, with current smokers having fewer long-term care admissions (HR 0.76, 95% CI 0.62-0.95). There was no difference between the statin and placebo groups in terms of time to long-term care (Fig. 1) . Using competing risk models for death and admission to long-term care, no between-group differences were observed (Figs. 2, 3 ).
Discussion
We did not show a difference in long-term care admission between those prescribed statins or placebo over the course of the two large RCTS. Admission to long-term care can be considered a proxy for frailty and functional decline, and our data would suggest no legacy effect of mid-to later-life statin prescribing on these important outcomes. This is aligned with other data describing statins and functional decline [3, 4] . An alternative interpretation of our results is that we did not demonstrate any statin-related harm, whereas previous studies have suggested the possibility of statins increasing the rates of institutionalisation for certain patient groups [19] . The potency and dose of statins used in the two RCTs is modest by contemporary standards and it remains possible that high-dose potent statins may have effects on the patterns of admission to long-term care.
The strongest, independent associations for incident carehome admission were age, sex, socioeconomic status and smoking. The association of smoking with reduced carehome status seems counterintuitive and not in keeping with our understanding of the effect on smoking in older age [20] . This finding is likely a result of survival bias and emphasises the importance of competing risk analyses in this field of research. A recent systematic review of associations with care-home admission from hospital also reported the importance of age and sex [21] . Other factors in that review with strong association, including dementia and disability, could not be assessed in our study as these were exclusion criteria for the included studies. In reviews looking at long-term care admission from community settings, dementia and factors relating to support networks and carer burden seem to be associated with this decision [22] . These findings highlight that admission to long-term care is a multifaceted decision and only certain aspects of this process could plausibly be influenced by statin prescribing.
There are several strengths to our approach. We used multimodal data to assign care-home status following best practice in 'big data' research [23] . The ability to link data from clinical trial cohorts to routinely collected health and social care data offers the potential to economically ascertain longer-term outcomes than would be possible within the primary study. Our results suggest that it is feasible to use routinely collected health and social care data to assign outcomes that may be of greatest relevance to older adults-in this case, using admission to long-term care as a surrogate for cognitive and functional decline. By using data from RCTs, we have large numbers of study-quality data. Baseline randomisation should avoid those biases associated with observational data on statins (e.g. confounding by indication, healthy user bias, healthy tolerater bias). Our previous work on the long-term follow-up of the WOSCOPS and PROS-PER trials has demonstrated the additional scientific value of extended follow-up of these clinical trial populations, and of record linkage to national datasets [1] . However, there are limitations to our methodology. For our analysis of statins, we have not corrected for life-course statin exposure. Ideally, we would have corrected our analyses with individual patient-level data regarding treatment modification, adherence, and achieved levels of low-density lipoprotein cholesterol. In population-based analyses, this level of granularity is not possible. However, we know from other studies that adherence and persistence are important issues, particularly in the older adult population [24] . We also recognise that we may have missed incident care-home admission if it occurred early after the trial and the patient was no longer resident during the time periods we selected for analyses. The majority of older adults are now prescribed statins at some point [25] and it seems likely that many in the placebo arm of the original trials will have also eventually been prescribed statins. This crossover may weaken the power of our analysis to demonstrate a modest statin effect. Thus, our analysis can only tell us about a potential legacy effect of previous statin administration. Describing the future effects of earlier-life statin exposure remains a valid question. In other longer term follow-up studies of statin trials, a persisting benefit from earlier treatment is consistently observed [26, 27] . For example, after the end of WOSCOPS, the use of lipid-lowering therapy during the first 5 years of extended follow-up was monitored by review of case records (in the original pravastatin and placebo groups, respectively, the proportion of subjects receiving statin therapy were 28.6 and 24.3% at 1 year post-trial, 33.6 and 29.4% at 3 years, and 38.7 and 35.2% at 5 years) [1] . That the initial treatment arm continues to show differential cardiovascular and other outcomes speaks to the legacy effect of statin exposure earlier in life. Our analysis had a specific focus around functional decline, and we recognise that despite the increasing numbers of large trials of statins in older adults, many questions remain around statins in older age [28] .
Conclusion
We did not demonstrate an association between several years of statin use in mid or later life and future long-term care admission, and a direct link between statins and admission to long-term care seems unlikely. The strongest associations with incident long-term care admission were non-modifiable factors of age and sex, as well as socioeconomic deprivation.
